Dublin, Feb. 09, 2024 (GLOBE NEWSWIRE) -- The "Pneumococcal Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028" report has been added to ResearchAndMarkets.com's offering.
The Global Pneumococcal Vaccine Market has experienced a significant surge in growth, with its valuation at USD 9.63 billion in 2022. This market analysis projects an impressive CAGR of 6.26% from 2022 to 2028, signaling a robust expansion over the next six years. The market's progression is bolstered by the increased global awareness of pneumococcal diseases and expansive immunization programs. The market is projected at 13.78 billion by 2028.
Key Market Drivers and Opportunities
Rising global awareness of the severe health implications of pneumococcal diseases has been a crucial driver of market growth. Educational campaigns and public health initiatives have substantially increased understanding and urgency around preventing these life-threatening illnesses. With governments incorporating vaccination programs into national healthcare strategies, access to vaccines has broadened, driving demand across various demographic groups. The ongoing COVID-19 pandemic has also heightened public and institutional awareness about the importance of vaccines to global health safety nets. This awareness, combined with the boost in vaccine manufacturing infrastructure, positions pneumococcal vaccines as an essential element of pandemic preparedness and response.
Pharmaceutical innovations continue to play a defining role in market expansion. Advanced vaccine formulations, such as Pneumococcal Conjugate Vaccines (PCVs), have improved efficacy and have proven to be fundamental in preventing infections from a multitude of pneumococcal strains. Additionally, these innovations have fostered expanded age group targeting for vaccinations, further broadening the market. The profound public health impact of effectively administered pneumococcal vaccines is indisputable. There has been a marked decrease in pneumococcal infections, hospitalizations, and mortality rates - particularly in at-risk populations such as children and the elderly. These improvements in public health support ongoing market growth.
Key Market Challenges
Addressing economic disparities in vaccine accessibility between countries remains a significant challenge. Supply chain efficiency, especially in maintaining vaccine efficacy through proper storage conditions, presents logistical challenges that impact market potential. Furthermore, continuously evolving Streptococcus pneumoniae serotypes necessitate relentless vaccine development and optimization.
Emerging Trends
The market is witnessing substantial developments with the introduction of next-generation pneumococcal vaccines that promise broader and more effective protection. The convergence of vaccines in combination products is facilitating immunization efficiency and is anticipated to drive future market growth. Innovative vaccine delivery technologies, including needle-free systems, present groundbreaking approaches to streamline vaccination processes, enhancing accessibility particularly in areas with limited resources.
Regional Market Analysis
In the forecast period, North America is expected to continue commanding a considerable share of the Global Pneumococcal Vaccine Market. Factors feeding into this dominance include a strong presence of key market players, sophisticated healthcare systems, and active government participation in vaccination initiatives. Recent vaccine approvals and the expansion of vaccination programs underscore the region's commitment to combating pneumococcal diseases and support the prediction of continued market growth.
Competitive Landscape
The competitive landscape showcases detailed analyses of the major companies within the Global Pneumococcal Vaccine Market. Through proactive strategies and innovations, these market players contribute to the industry's growth trajectory and public health improvements worldwide.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 178 |
| Forecast Period | 2022-2028 |
| Estimated Market Value (USD) in 2022 | $9.63 Billion |
| Forecasted Market Value (USD) by 2028 | $13.78 Billion |
| Compound Annual Growth Rate | 6.2% |
| Regions Covered | Global |
A selection of companies mentioned in this report includes:
- GSK PLC
- Pfizer Inc
- Merck KGaA
- Serum Institute of India Pvt. Ltd.
- CSL Ltd
- Sanofi SA
- Walvax Biotechnology Co. Ltd.
- Beijing Minhai Biotechnology Limited Company
For more information about this report visit https://www.researchandmarkets.com/r/1962r3
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
